Previous 10 | Next 10 |
Multi-centre, d ouble-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therap y in anorexia nervosa for which there is currently no approved pharmacological treatment option ...
Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam war and is still the preferred anesthetic in battlefield situations...
Compass Pathways has announced that it will be replacing its chief executive officer by the end of the month. The company’s founder, CEO and chair, George Goldsmith, will be replaced as CEO by Kabir Nath, effective Aug. 1, 2022. The mental health company announced on its website ...
LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2022, and provide...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips State and federal governments have played a larger role when it comes to approving illegal substances. Most notably, cannabis stocks have been in focus over the last few years, as various government bodies have given mariju...
When a psychedelic substance gets to Phase 3 trials, like the one completed by the Multidisciplinary Association for Psychedelic Studies ( MAPS ) with MDMA in August 2021, there is a general sense of relief. It’s been a long journey from Phase 1 for most s...
COMPASS Pathways ( NASDAQ: CMPS ) appointed Kabir Nath as CEO, effective Aug.1, 2022; current CEO and chairman George Goldsmith will serve as Executive Chairman from Aug.1 to Dec.31, 2022. for facilitating transition and then remain as chairman. Most re...
Kabir Nath will build upon COMPASS’ success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care George Goldsmith remains COMPASS’ Chairman London, UK – Jul...
We have seen the psychedelic industry grow significantly the last few years as investing companies pour more money into the burgeoning space and organizations respond to the global mental disorder epidemic. A Lancet study found that the worldwide pandemic has impacted individuals’ ...
The psychedelics renaissance is in an expanded growth mode, not just in the U.S. and Canada, but in other countries as well. But everywhere in the world, it’s a bit of a Dr. Jekyll/Mr. Hyde scenario: startup businesses ostensibly building a serious moneymaking enterpr...
News, Short Squeeze, Breakout and More Instantly...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...